Related Experiment Videos
Nontuberculous mycobacterial infections
A L French1, D A Benator, F M Gordin
1Department of Medicine, Rush Medical College, Chicago, Illinois, USA.
Abstract:
The acquired immunodeficiency syndrome (AIDS) pandemic has led to greater understanding and respect for the pathogenic potential of non-tuberculous mycobacteria. Mycobacterium avium complex (MAC) has emerged as the most common systemic bacterial infection in AIDS, causing debilitating disseminated disease in late-stage HIV-infected patients. With the release of the macrolide antibiotics, clarithromycin and azithromycin, effective and well-tolerated therapeutic regimens for MAC have been developed which prolong survival and increase quality of life. The macrolides and rifabutin are also effective as preventive therapy for MAC in patients with AIDS. Mycobacterium kansasii, which causes pulmonary disease similar to tuberculosis as well as disseminated disease in AIDS, is treatable with isoniazid, rifampin and ethambutol. Clinical syndromes and therapeutic options for other non-tuberculous mycobacteria in AIDS are also reviewed.
Insights
The acquired immunodeficiency syndrome (AIDS) pandemic highlights non-tuberculous mycobacteria, with Mycobacterium avium complex (MAC) being common in advanced HIV. Effective macrolide antibiotics and rifabutin improve treatment and prevention for MAC and Mycobacterium kansasii infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Immunology
Background:
- The acquired immunodeficiency syndrome (AIDS) pandemic has increased awareness of non-tuberculous mycobacteria (NTM) pathogenicity.
- Mycobacterium avium complex (MAC) is the most frequent systemic bacterial infection in AIDS patients, leading to disseminated disease in advanced HIV.
- Understanding NTM infections is crucial for managing opportunistic infections in immunocompromised individuals.
Purpose of the Study:
- To review the clinical syndromes caused by NTM in AIDS patients.
- To outline current and emerging therapeutic options for NTM infections in the context of HIV/AIDS.
- To highlight the impact of new antibiotics on managing MAC and other NTM.
Main Methods:
- Literature review of clinical syndromes and treatment strategies for NTM in AIDS.
- Analysis of the efficacy of macrolide antibiotics (clarithromycin, azithromycin) and rifabutin for MAC treatment and prophylaxis.
- Review of treatment regimens for Mycobacterium kansasii, including isoniazid, rifampin, and ethambutol.
Main Results:
- Macrolide antibiotics and rifabutin offer effective and well-tolerated treatment for MAC, prolonging survival and improving quality of life in AIDS patients.
- Preventive therapy with macrolides and rifabutin is beneficial for MAC in AIDS.
- Mycobacterium kansasii infections, presenting as pulmonary or disseminated disease in AIDS, are treatable with standard anti-tuberculosis drugs.
Conclusions:
- Effective therapeutic and preventive strategies exist for MAC and Mycobacterium kansasii in AIDS patients.
- Advances in antibiotic therapy, particularly macrolides, have significantly improved outcomes for MAC infections.
- Continued research and clinical vigilance are necessary to manage the spectrum of NTM infections in the evolving landscape of HIV/AIDS treatment.